The present invention relates to a pharmaceutical composition for preventing, suppressing, or treating the symptoms that accompany pseudo-allergic reactions, said pharmaceutical composition comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action or a pharmaceutically acceptable salt of this compound.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
The present invention relates to a pharmaceutical composition for preventing, suppressing, or treating a symptom associated with an allergic reaction, the pharmaceutical composition including a compound having a P2X4 receptor antagonizing action or a pharmaceutically acceptable salt thereof as an active ingredient.
The present invention pertains to a pharmaceutical composition that is for preventing, suppressing, or treating symptoms associated with an allergic reaction and that includes a compound having a P2X4 receptor antagonist effect or a pharmacologically acceptable salt of the compound as an active ingredient.
Provided are a liver cell culture membrane and a drug transport ability evaluation kit that are to be used for in vitro, easily and directly evaluating drug transport ability, i.e., between the migration of an administered drug from the liver into blood vessels followed by whole body migration and the migration of the drug into bile in the bile duct followed by biliary excretion, which is more dominantly induced and to what extent, as one of important factors of distribution, metabolism and excretion. The liver cell culture membrane 14 comprises a membrane-type cell layer 12 which is formed by cells 12a, such as liver cancer cells, cultured in a membrane form on a porous plastic film 13, wherein the cells 12a have such an orientation property that the blood vessel side becomes the bottom side of the membrane-type cell layer 12 while the bile duct side becomes the top side of the membrane-type cell layer 12. The drug transport ability evaluation kit 1 is provided with: a liver cell culture membrane-holding insert container 10 containing the liver cell culture membrane 14, which is disposed on the bottom thereof, and housing a first test solution 15; and a well plate 20 comprising a well 21, into which the insert container is inserted, and housing a second test solution 25 in which the liver cell culture membrane 14 is to be immersed.
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (Japan)
TAKASAKI UNIVERSITY OF HEALTH AND WELFARE (Japan)
Inventor
Shimada, Junko
Suto, Yutaka
Abstract
22, R1is a hydrogen atom, an alkoxy group having 1 to 4 carbon atoms, or an alkyl group having 1 to 10 carbon atoms which may be branched, R2is a hydrogen atom, halogen, an alkyl group having 1 to 10 carbon atoms which may be branched, a cycloalkyl group having 3 to 8 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms, R3is a hydrogen atom, an alkyl group having 1 to 10 carbon atoms which may be branched, or an alkoxy group having 1 to 4 carbon atoms, and R4is a cycloalkyl group having 3 to 8 carbon atoms, a pyridyl group which may have a substituent, a pyrimidyl group which may have a substituent, a pyrazyl group which may have a substituent, a piperidyl group which may have a substituent, a piperazyl group which may have a substituent, a group represented by R41, a group represented by R42, a group represented by R43, or a group represented by R44.
C07C 233/61 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
The present invention pertains to a pharmaceutical composition that is for preventing, suppressing, or treating symptoms associated with an allergic reaction and that includes a compound having a P2X4 receptor antagonist effect or a pharmacologically acceptable salt of the compound as an active ingredient.
The present invention relates to a pharmaceutical composition for preventing, suppressing, or treating a symptom associated with a pseudo-allergic reaction, the pharmaceutical composition including a compound having a P2X4 receptor antagonizing action or a pharmaceutically acceptable salt thereof as an active ingredient.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
patents
